1966. Protection afforded by prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections.

BACKGROUND: Protection offered by five different forms of immunity, combining natural and vaccine immunity, was investigated against symptomatic SARS-CoV-2 infection from Omicron BA.1 or BA.2, and severe, critical, or fatal COVID-19 from BA.1 or BA.2, in Qatar, between December 23, 2021 and February...

Descripción completa

Detalles Bibliográficos
Autores principales: Altarawneh, Heba N, Chemaitelly, Hiam, Ayoub, Houssein H, Tang, Patrick, Hasan, Mohammad R, Yassine, Hadi M, Al-Khatib, Hebah A, Smatti, Maria K, Coyle, Peter, Al-Kanaani, Zaina, Al-Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul-Rahim, Hanan F, Nasrallah, Gheyath K, Al-Kuwari, Mohamed Ghaith, Butt, Adeel A, Al-Romaihi, Hamad Eid, Al-Thani, Mohamed H, Al Khal, Abdul Latif, Bertollini, Roberto, Abu-Raddad, Laith J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752683/
http://dx.doi.org/10.1093/ofid/ofac492.1591
Descripción
Sumario:BACKGROUND: Protection offered by five different forms of immunity, combining natural and vaccine immunity, was investigated against symptomatic SARS-CoV-2 infection from Omicron BA.1 or BA.2, and severe, critical, or fatal COVID-19 from BA.1 or BA.2, in Qatar, between December 23, 2021 and February 21, 2022. METHODS: Six national, matched, test-negative case-control studies were conducted on a sample of 272,861 PCR-positive tests and 669,628 PCR-negative tests to estimate effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine, mRNA-1273 (Moderna) vaccine, natural immunity due to prior infection with pre-Omicron variants, and hybrid immunity from prior infection and vaccination. RESULTS: Effectiveness of prior infection alone against symptomatic BA.2 infection was 46.1% (95% CI: 39.5-51.9%). Effectiveness of two-dose BNT162b2 vaccination alone was negligible at -1.1% (95% CI: -7.1-4.6), but nearly all individuals received their second dose >6 months earlier. Effectiveness of three-dose BNT162b2 vaccination alone was 52.2% (95% CI: 48.1-55.9%). Effectiveness of hybrid immunity of prior infection and two-dose BNT162b2 vaccination was 55.1% (95% CI: 50.9-58.9%). Effectiveness of hybrid immunity of prior infection and three-dose BNT162b2 vaccination was 77.3% (95% CI: 72.4-81.4%). Meanwhile, prior infection, BNT162b2 vaccination, and hybrid immunity all showed strong effectiveness ( >70%) against severe, critical, or fatal COVID-19 due to BA.2. Similar patterns of effectiveness were observed for BA.1 and for the mRNA-1273 vaccine. [Figure: see text] [Figure: see text] CONCLUSION: There are no discernable differences between BA.1 and BA.2 in the effects of prior infection, vaccination, and hybrid immunity. Vaccination enhances the protection of those with a prior infection. Hybrid immunity resulting from prior infection and recent booster vaccination conferred the strongest protection. DISCLOSURES: Adeel A. Butt, MBBS, Gilead Sciences: Grant/Research Support.

Ejemplares similares